1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

IBCL - 141

Golcadomide, a Potential First-in-Class, Oral Celmod ± Rituximab in the Phase 1/2 CC-99282-NHL-001 Study: Long-Term Follow-Up Results of Patients With Relapsed/Refractory Follicular Lymphoma

$Preview of Golcadomide, a Potential First-in-Class, Oral Celmod ± Rituximab in the Phase 1/2 CC-99282-NHL-001 Study: Long-Term Follow-Up Results of Patients With Relapsed/Refractory Follicular Lymphoma$

View Poster Contact Presenter

Poster Presenter

Javier Munoz

Authors

Javier Munoz

Part of Topic

Indolent B-Cell Lymphoma (IBCL)